191 related articles for article (PubMed ID: 22560595)
1. The dopaminergic stabilizer, (-)-OSU6162, rescues striatal neurons with normal and expanded polyglutamine chains in huntingtin protein from exposure to free radicals and mitochondrial toxins.
Ruiz C; Casarejos MJ; Rubio I; Gines S; Puigdellivol M; Alberch J; Mena MA; de Yebenes JG
Brain Res; 2012 Jun; 1459():100-12. PubMed ID: 22560595
[TBL] [Abstract][Full Text] [Related]
2. Astrocytes from cortex and striatum show differential responses to mitochondrial toxin and BDNF: implications for protection of striatal neurons expressing mutant huntingtin.
Saba J; López Couselo F; Turati J; Carniglia L; Durand D; de Laurentiis A; Lasaga M; Caruso C
J Neuroinflammation; 2020 Oct; 17(1):290. PubMed ID: 33023623
[TBL] [Abstract][Full Text] [Related]
3. Striatal cells from mutant huntingtin knock-in mice are selectively vulnerable to mitochondrial complex II inhibitor-induced cell death through a non-apoptotic pathway.
Ruan Q; Lesort M; MacDonald ME; Johnson GV
Hum Mol Genet; 2004 Apr; 13(7):669-81. PubMed ID: 14962977
[TBL] [Abstract][Full Text] [Related]
4. Profile of pridopidine and its potential in the treatment of Huntington disease: the evidence to date.
Squitieri F; de Yebenes JG
Drug Des Devel Ther; 2015; 9():5827-33. PubMed ID: 26604684
[TBL] [Abstract][Full Text] [Related]
5. Pridopidine protects neurons from mutant-huntingtin toxicity via the sigma-1 receptor.
Eddings CR; Arbez N; Akimov S; Geva M; Hayden MR; Ross CA
Neurobiol Dis; 2019 Sep; 129():118-129. PubMed ID: 31108174
[TBL] [Abstract][Full Text] [Related]
6. Brain-derived neurotrophic factor modulates dopaminergic deficits in a transgenic mouse model of Huntington's disease.
Pineda JR; Canals JM; Bosch M; Adell A; Mengod G; Artigas F; Ernfors P; Alberch J
J Neurochem; 2005 Jun; 93(5):1057-68. PubMed ID: 15934928
[TBL] [Abstract][Full Text] [Related]
7. Calcineurin is involved in the early activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells.
Xifró X; García-Martínez JM; Del Toro D; Alberch J; Pérez-Navarro E
J Neurochem; 2008 Jun; 105(5):1596-612. PubMed ID: 18221365
[TBL] [Abstract][Full Text] [Related]
8. Human dental pulp stem cells protect mouse dopaminergic neurons against MPP+ or rotenone.
Nesti C; Pardini C; Barachini S; D'Alessandro D; Siciliano G; Murri L; Petrini M; Vaglini F
Brain Res; 2011 Jan; 1367():94-102. PubMed ID: 20854799
[TBL] [Abstract][Full Text] [Related]
9. BDNF overexpression in the forebrain rescues Huntington's disease phenotypes in YAC128 mice.
Xie Y; Hayden MR; Xu B
J Neurosci; 2010 Nov; 30(44):14708-18. PubMed ID: 21048129
[TBL] [Abstract][Full Text] [Related]
10. FK506 ameliorates cell death features in Huntington's disease striatal cell models.
Rosenstock TR; de Brito OM; Lombardi V; Louros S; Ribeiro M; Almeida S; Ferreira IL; Oliveira CR; Rego AC
Neurochem Int; 2011 Oct; 59(5):600-9. PubMed ID: 21703318
[TBL] [Abstract][Full Text] [Related]
11. The common inhaled anesthetic isoflurane increases aggregation of huntingtin and alters calcium homeostasis in a cell model of Huntington's disease.
Wang Q; Liang G; Yang H; Wang S; Eckenhoff MF; Wei H
Toxicol Appl Pharmacol; 2011 Feb; 250(3):291-8. PubMed ID: 21059370
[TBL] [Abstract][Full Text] [Related]
12. Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation.
Wang J; Gines S; MacDonald ME; Gusella JF
BMC Neurosci; 2005 Jan; 6():1. PubMed ID: 15649316
[TBL] [Abstract][Full Text] [Related]
13. Neuroprotective effect of the antiparkinsonian drug pramipexole against nigrostriatal dopaminergic degeneration in rotenone-treated mice.
Inden M; Kitamura Y; Tamaki A; Yanagida T; Shibaike T; Yamamoto A; Takata K; Yasui H; Taira T; Ariga H; Taniguchi T
Neurochem Int; 2009 Dec; 55(8):760-7. PubMed ID: 19647776
[TBL] [Abstract][Full Text] [Related]
14. Striatal neurons expressing full-length mutant huntingtin exhibit decreased N-cadherin and altered neuritogenesis.
Reis SA; Thompson MN; Lee JM; Fossale E; Kim HH; Liao JK; Moskowitz MA; Shaw SY; Dong L; Haggarty SJ; MacDonald ME; Seong IS
Hum Mol Genet; 2011 Jun; 20(12):2344-55. PubMed ID: 21447599
[TBL] [Abstract][Full Text] [Related]
15. Dopamine enhances motor and neuropathological consequences of polyglutamine expanded huntingtin.
Cyr M; Sotnikova TD; Gainetdinov RR; Caron MG
FASEB J; 2006 Dec; 20(14):2541-3. PubMed ID: 17065224
[TBL] [Abstract][Full Text] [Related]
16. Mechanism of the neuroprotective role of coenzyme Q10 with or without L-dopa in rotenone-induced parkinsonism.
Abdin AA; Hamouda HE
Neuropharmacology; 2008 Dec; 55(8):1340-6. PubMed ID: 18817789
[TBL] [Abstract][Full Text] [Related]
17. Dysregulation of gene expression in primary neuron models of Huntington's disease shows that polyglutamine-related effects on the striatal transcriptome may not be dependent on brain circuitry.
Runne H; Régulier E; Kuhn A; Zala D; Gokce O; Perrin V; Sick B; Aebischer P; Déglon N; Luthi-Carter R
J Neurosci; 2008 Sep; 28(39):9723-31. PubMed ID: 18815258
[TBL] [Abstract][Full Text] [Related]
18. Expression, pharmacology and functional activity of adenosine A1 receptors in genetic models of Huntington's disease.
Ferrante A; Martire A; Pepponi R; Varani K; Vincenzi F; Ferraro L; Beggiato S; Tebano MT; Popoli P
Neurobiol Dis; 2014 Nov; 71():193-204. PubMed ID: 25132555
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of Bim contributes to the potentiation of serum deprivation-induced apoptotic cell death in Huntington's disease knock-in striatal cell line.
Kong PJ; Kil MO; Lee H; Kim SS; Johnson GV; Chun W
Neurol Res; 2009 Feb; 31(1):77-83. PubMed ID: 18691453
[TBL] [Abstract][Full Text] [Related]
20. Participation of par-4 in the degeneration of striatal neurons induced by metabolic compromise with 3-nitropropionic acid.
Duan W; Guo Z; Mattson MP
Exp Neurol; 2000 Sep; 165(1):1-11. PubMed ID: 10964480
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
